Expert working groups

The basic aim of the expert working groups/centres of the IHBT is to coordinate the treatment of patients, management of clinical trials, clinical and laboratory research projects in patients with a given diagnosis, at the diagnostic, therapeutic and research level.

AML Working Group

The AML Working Group is responsible for the diagnosis and treatment of patients with acute myeloid leukaemia at the Institute of Haematology and Blood Transfusion. It provides a space to bring together clinicians and laboratory complement staff to discuss and effectively share information regarding the diagnosis and therapy of individual patients. The group also collaborates closely with the scientific teams at the IHBT in the field of applied research in AML in particular and myeloid malignancies in general. Members of the group participate in the organisation and conduct of clinical trials related to AML conducted at the IHBT and also, in the context of clinical research and information sharing, cooperate with other haematology centres in the Czech Republic and abroad. Members of the group also present the results of their work at professional hematology events in the Czech Republic and abroad and publish in international and national journals.

The clinical coordinator is MUDr. Jan Válka, Ph.D. ( jan.valka@uhkt.cz )

Working group for ALL

The clinical coordinator is MUDr. Mgr. Cyril Šálek, Ph.D. ( cyril.salek@uhkt.cz )

Working Group for CML

The CML Working Group addresses the issue of patients diagnosed with chronic myeloid leukemia. Whether it is a precise diagnosis, as well as therapy with all available treatment options. Comprehensive care is only possible with intensive cooperation between the doctors of the clinical department and the staff of the complement of laboratories, as well as the scientific teams of the research department, the most intensive cooperation being with the highly accredited department of molecular genetics. There is also intensive cooperation with other haematological care centres in the Czech Republic and Europe on joint clinical and laboratory projects. Clinical trials related to CML are also addressed, including the introduction of new drugs into clinical practice. The group members present the results of their work at professional haematology events in the Czech Republic and abroad, as well as through publications in domestic and international journals.

Clinical coordinator MUDr. Hana Klamová, CSc. ( hana.klamova@uhkt.cz)

Laboratory coordinator doc. Mgr. Kateřina Machová Poláková, Ph.D. ( katerina.machova@uhkt.cz)

Working Group on Lymphoproliferative Diseases + CAR-T

Clinical coordinator is Robert Pytlík, M.D., Ph.D. ( robert.pytlik@uhkt.cz)

Working Group on MDS

The MDS Group co-organizes the activities of the national MDS Working Group (Czech MDS Group), supports the activities of the MDS Patients Association, and conducts educational activities at national and international events.

The clinical coordinator of the group is MUDr. Markéta Št'astná Marková, CSc. ( marketa.markova@uhkt.cz)

Myeloproliferative Diseases Working Group

The Working Group on Ph-myeloproliferative Diseases at the Institute of Hematology and Blood Transfusion (IHBT) specializes in the diagnosis and treatment of Ph-negative myeloproliferative diseases. These diseases include true polycythemia, essential thrombocythemia and primary myelofibrosis. We are also involved in the diagnosis and treatment of rare Ph- myeloproliferative diseases such as chronic neutrophilic leukemia and chronic eosinophilic leukemia, as well as myelodysplastic-myeloproliferative diseases (e.g., atypical chronic myeloid leukemia).

Within the IHBT, we provide comprehensive care to patients, which includes specialized diagnostics including molecular genetic testing, individualized treatment using the most modern procedures available, the possibility of participating in clinical trials testing new therapeutic agents, regular monitoring of the course of the disease and response to treatment, and consultations for physicians from other departments.

Our team works closely with other experts both within the Czech Myeloproliferative Working Group (CZEMP) and the international Central European Myeloproliferative Neoplasm Organisation (CEMPO). We are actively involved in the research of these diseases and participate in international clinical trials. We are authors/co-authors of national recommendations for diagnosis and treatment of these groups. We participate in undergraduate and postgraduate training of physicians.

For patients and their loved ones, we offer comprehensive care in one location, consultations with leading experts in the field, access to the latest treatment options, supportive and palliative care.

The clinical coordinator is Jindřich Polívka, MD, MHA ( jindrich.polivka@uhkt.cz)

Centre for the diagnosis and treatment of rare congenital and acquired red blood cell disorders

The department provides urgent and consilient care for patients from other countries and different ethnicities due to the high incidence of some congenital red blood cell diseases in non-European regions within the European Reference Network as a EuroBloodNet Centre.

The responsible person is Prof. MUDr. J. Čermák, CSc. ( jaroslav.cermak@uhkt.cz)

Centre for Diagnosis and Treatment of Rare Disorders of Haemostasis

The responsible person is Peter Salaj, MD. ( peter.salaj@uhkt.cz)